How did the discoveries of BRCA1 and BRCA2 link inherited mutations to cancer risk?

The discovery of BRCA1 and BRCA2 represents a landmark achievement in translational medicine, bridging the gap between basic genetic research and clinical practice. These genes normally function as tumor suppressor genes, playing a critical role in maintaining genetic integrity by repairing DNA damage.1

The link between these genes and cancer risk was established by identifying that inherited mutations hinder a cell's ability to repair DNA. When an individual inherits a mutated copy, they are more prone to experiencing further mutations, which can lead to the development of breast cancer, ovarian cancer, and other malignancies.12

This discovery enabled the rapid development of genetic testing, allowing for personalized risk assessment. In the context of translational medicine, this knowledge empowers high-risk individuals to engage in proactive health management, such as increased screening frequency, lifestyle modifications, and prophylactic surgeries like mastectomy. By translating laboratory findings into clinical tools, these discoveries have fundamentally shifted the approach to cancer prevention and personalized medicine.13